Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes

Journal of Clinical Virology

Volumn 44, Issue 4, 2009, Pages 325-328

  Covens, Kris ^a   Kabeya, Kabamba ^b   Schrooten, Yoeri ^a,c   Dekeersmaeker, Nathalie ^a   Van Wijngaerden, Eric ^c   Vandamme, Anne Mieke ^a   De Wit, Stéphane ^b   Van Laethem, Kristel ^a,c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Enfuvirtide; Resistance development; Subtypes

Indexed keywords

ENFUVIRTIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; SALVAGE THERAPY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 62749199716     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.01.012     Document Type: Article

References (17)

1. Kilgore N.R., Salzwedel K., Reddick M., Allaway G.P., and Wild C.T. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 77 (2003) 7669-7672
2. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91 (1994) 9770-9774
3. Aghokeng A.F., Ewane L., Awazi B., Nanfack A., Delaporte E., Zekeng L., et al. Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa. AIDS Res Hum Retroviruses 21 (2005) 430-433
4. Razzolini F., Vicenti I., Saladini F., Micheli V., Romano L., Cargnel A., et al. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses 23 (2007) 558-563
5. Sista P.R., Melby T., Davison D., Jin L., Mosier S., Mink M., et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18 (2004) 1787-1794
6. Melby T., Sista P., DeMasi R., Kirkland T., Roberts N., Salgo M., et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 22 (2006) 375-385
7. Chinnadurai R., Münch J., Dittmar M.T., and Kirchhoff F. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 19 (2005) 1919-1922
8. Poveda E., Barreiro P., Rodés B., and Soriano V. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses 21 (2005) 583-585
9. Renjifo B., and Essex M. HIV-1 subtypes and recombinants. AIDS in Africa. 2nd ed. (2002), Kluwer Academic-Plenum Publishers, New York p. 138-57
10. Abecasis A.B., Deforche K., Snoeck J., Bacheler L.T., McKenna P., Carvalho A.P., et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19 (2005) 1799-1806
11. Abecasis A.B., Deforche K., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther 11 (2006) 581-589
12. Brenner B., Turner D., Oliveira M., Moisi D., Detorio M., Carobene M., et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 3 (2003) F1-F5
13. Brenner B.G., Oliveira M., Doualla-Bell F., Moisi D.D., Ntemgwa M., Frankel F., et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20 (2006) F9-F13
14. Deforche K., Silander T., Camacho R., Grossman Z., Soares M.A., Van Laethem K., et al. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 22 (2006) 2975-2979
15. Van Laethem K., Schrooten Y., Lemey P., Van Wijngaerden E., De Wit S., Van Ranst M., et al. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 123 (2005) 25-34
16. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-800 (http://jose.med.kuleuven.be/subtypetool/html/index.html).
17. Cabrera C., Marfil S., García E., Martinez-Picado J., Bonjoch A., Bofill M., et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 20 (2006) 2075-2080